PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.35%
Negative revenue growth while AVGO stands at 0.07%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
0.52%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
-16.03%
Negative EBIT growth while AVGO is at 32.81%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-5.08%
Negative operating income growth while AVGO is at 32.81%. Joel Greenblatt would press for urgent turnaround measures.
-4.78%
Negative net income growth while AVGO stands at 137.82%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.81%
Negative EPS growth while AVGO is at 137.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-4.90%
Negative diluted EPS growth while AVGO is at 138.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.20%
Share count expansion well above AVGO's 0.25%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.10%
Diluted share reduction more than 1.5x AVGO's 4.28%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-0.00%
Dividend reduction while AVGO stands at 101.84%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-42.68%
Negative OCF growth while AVGO is at 0.07%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-47.69%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
54.04%
10Y revenue/share CAGR under 50% of AVGO's 503.24%. Michael Burry would suspect a lasting competitive disadvantage.
24.84%
5Y revenue/share CAGR under 50% of AVGO's 351.42%. Michael Burry would suspect a significant competitive gap or product weakness.
23.53%
3Y revenue/share CAGR under 50% of AVGO's 264.31%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
107.34%
10Y OCF/share CAGR under 50% of AVGO's 18241.73%. Michael Burry would worry about a persistent underperformance in cash creation.
102.79%
Below 50% of AVGO's 497.69%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
86.39%
3Y OCF/share CAGR under 50% of AVGO's 268.71%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
179.18%
Below 50% of AVGO's 2036.42%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
330.89%
5Y net income/share CAGR above 1.5x AVGO's 17.40%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
121.75%
3Y net income/share CAGR above 1.5x AVGO's 11.31%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
36.24%
Equity/share CAGR of 36.24% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
10.06%
Below 50% of AVGO's 472.89%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
8.51%
Below 50% of AVGO's 296.98%. Michael Burry suspects a serious short-term disadvantage in building book value.
1145.59%
Dividend/share CAGR of 1145.59% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
193.66%
Below 50% of AVGO's 812.58%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
66.64%
Below 50% of AVGO's 333.82%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
5.52%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
2.96%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.76%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.38%
BV/share growth above 1.5x AVGO's 0.36%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.95%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.58%
R&D growth drastically higher vs. AVGO's 0.25%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
6.81%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.